{"prompt": "['12 Organization of the study', '12.1 Scientific committee', \"The Scientific Committee for the study, presided over by the study's main investigator,\", 'will be composed of investigators (one ENT specialist, one geneticist), the', 'methodologist and the sponsor of the study. The committee will be responsible for', 'validating the definitive version of the protocol, supervising the implementation and', 'running of the study, and for writing the reports and publications resulting from the', 'study.', '12.2 Independent monitoring and safety committee for the study', 'Monitoring the safety of administration of the product, motivated by the iatrogenic risks,', 'justifies the setting up of a specific independent monitoring and safety committee.', 'This committee will meet as defined in paragraph 2.3. The first meeting will occur after', 'collection of adverse events and observance of the treatment after 30 days for the 8', 'first patients included.', 'The committee will give its recommandations on the continuation of the study.', 'DSMB recommendations will be forwarded to ANSM for information.', 'There will be two or three meetings depending on the tolerance of the product.', 'It will be composed of:', 'a specialist of the disease not involved in the study,', 'a ENT specialist,', 'a statistician specializing in the methodology of clinical trials.', '13', 'Medium and long term perspectives', 'Nosebleeds are a significant morbidity factor in HHT, not solely because of the anemia', 'they provoke, but also because of the handicap that they represent in the daily lives of', 'active patients.', 'In total, around 95% of the patients followed for HHT are concerned by nosebleeds.', 'Although the mortality rate for the patients followed for this disease is low, the morbidity', 'rate is severe and the psychosocial impact of HHT is almost constant in adults.', 'For most patients with severe nosebleeds, a regular nasal administration of tacrolimus', 'should make it possible in terms of clinical development to:', '-', 'obtain a significant reduction in nosebleed duration.', '-', 'decrease the monthly number of nosebleeds,', '-', 'increase hemoglobin and serum ferritin concentrations,', '-', 'decrease the number of local surgical and packing treatments, as well as the', 'intravenous perfusions of iron,', '-', 'decrease the number of blood transfusions sometimes needed in case of a too', 'great loss of blood,', '-', 'improve air flow and decrease nasal obstructions,', 'Page 55 of 64']['-', 'improve patient quality of life (possibility of going shopping, going to a', 'restaurant, enjoying meals with family, having a professional activity, etc.),', '-', 'decrease the number of consultations and/or hospitalizations,', '-', 'decrease the cost of management of severe nosebleeds given their current', 'costs (transfusions, iron supplementation, etc.).', 'The possible efficacy of a nasal administration of tacrolimus on nosebleeds would be', 'extremely interesting and would constitute significant progress to the extent that no', 'current treatments, either medical or surgical, have made it possible to significantly', 'decrease nosebleeds in the long term, with the exception of the closure of the nasal', 'cavities which remains an aggressive, last resort act.', 'In the long term, and should the product prove to be effective, it would be possible to', 'imagine regular nasal administrations of tacrolimus.', 'Page 56 of 64']['14 References', '1.', 'Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary', 'hemorrhagic telangiectasia and severe hepatic vascular malformations and high', 'cardiac output. JAMA : the journal of the American Medical Association. Mar', '7', '2012;307(9):948-955.', '2.', 'Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary', 'hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. Mar 6', '2000;91(1):66-67.', '3.', 'Moussouttas M, Fayad P, Rosenblatt M, et al. Pulmonary arteriovenous malformations:', 'cerebral ischemia and neurologic manifestations. Neurology. Oct 10 2000;55(7):959', '964.', '4.', 'Putman CM, Chaloupka JC, Fulbright RK, Awad IA, White RI, Jr., Fayad PB.', 'Exceptional multiplicity of cerebral arteriovenous malformations associated with', 'hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). AJNR Am J', 'Neuroradiol. Oct 1996;17(9):1733-1742.', '5.', 'Andersen PE, Kjeldsen AD, Oxhoj H, Vase P, White RI, Jr. Embolotherapy for', 'pulmonary arteriovenous malformations in patients with hereditary hemorrhagic', 'telangiectasia (Rendu-Osler-Weber syndrome). Acta Radiol. Nov 1998;39(6):723-726', '6.', 'Haitjema T, Balder W, Disch FJ, Westermann CJ. Epistaxis in hereditary haemorrhagic', 'telangiectasia. Rhinology. Sep 1996;34(3):176-178.', '7.', 'Kjeldsen AD, Andersen PE, Oxhoj H. [Picture of the month]. Ugeskr Laeger. Jun 19', '2000;162(25):3618.', '8.', 'Shovlin CL. Supermodels and disease: insights from the HHT mice. J Clin Invest. Nov', '1999;104(10):1335-1336.', '9.', 'Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary', 'arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.', 'Am J Respir Crit Care Med. May 1 2004;169(9):994-1000.', '10.', 'Krings T, Ozanne A, Chng SM, Alvarez H, Rodesch G, Lasjaunias PL. Neurovascular', 'phenotypes in hereditary haemorrhagic telangiectasia patients according to age.', 'Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology. Oct', '2005;47(10):711-720.', '11.', 'Krings T, Mull M, Gilsbach JM, Thron A. Spinal vascular malformations. Eur Radiol.', 'Feb 2005;15(2):267-278.', '12.', 'Morgan T, McDonald J, Anderson C, et al. Intracranial hemorrhage in infants and', 'children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).', 'Pediatrics. Jan 2002;109(1):E12', '13.', 'Matsubara S, Bourdeau A, terBrugge KG, Wallace C, Letarte M. Analysis of endoglin', 'expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke.', 'Nov 2000;31(11):2653-2660', '14.', 'Mandzia JL, terBrugge KG, Faughnan ME, Hyland RH. Spinal cord arteriovenous', 'malformations in two patients with hereditary hemorrhagic telangiectasia. Childs Nerv', 'Syst. Mar 1999;15(2-3):80-83.', '15.', 'Maher CO, Piepgras DG, Brown RD, Jr., Friedman JA, Pollock BE. Cerebrovascular', 'manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke. Apr', '2001;32(4):877-882.', '16.', 'Willemse RB, Mager JJ, Westermann CJ, Overtoom TT, Mauser H, Wolbers JG.', 'Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic', 'telangiectasia. J Neurosurg. May 2000;92(5):779-784.', '17.', 'Easey AJ, Wallace GM, Hughes JM, Jackson JE, Taylor WJ, Shovlin CL. Should', 'asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened', 'for cerebral vascular malformations? Data from 22,061 years of HHT patient life. J', 'Neurol Neurosurg Psychiatry. Jun 2003;74(6):743-748.', 'Page 57 of 64']\n\n###\n\n", "completion": "END"}